Table 1 Baseline disease characteristics of 210 patients with axial spondyloarthritis
Baseline parameters | Nr-axSpA (n = 95) | AS (n = 115) | All patients (n = 210) |
|---|---|---|---|
Age, years | 38.7 ± 9.9 | 36.8 ± 11.0 | 37.3 ± 10.6 |
Male gender, n (%) | 32 (33.7) | 75 (65.2) | 107 (51.0) |
HLA-B27 positive, n (%) | 69 (72.6) | 97 (84.3) | 166 (79.0) |
Duration of symptoms, years | 3.2 ± 2.2 | 5.2 ± 2.8 | 4.2 ± 2.7 |
BASDAI, points NRS (0–10) | 4.2 ± 2.0 | 3.8 ± 2.2 | 3.9 ± 2.2 |
Peripheral arthritis, n (%) | 16 (16.8) | 15 (13.0) | 31 (14.8) |
BASFI, points NRS (0–10) | 2.8 ± 2.2 | 3.0 ± 2.4 | 2.9 ± 2.3 |
BASMI, points (0–10) | 1.5 ± 1.5 | 2.0 ± 1.7 | 1.8 ± 1.6 |
CRP, mg/l | 6.5 ± 12.8 | 12.4 ± 16.6 | 9.7 ± 15.2 |
mSASSS, points (0–72) | 2.3 ± 4.2 | 5.9 ± 10.3 | 4.2 ± 8.3 |
NSAIDs intake, n (%) | 64 (67.4) | 76 (66.1) | 140 (66.7) |
Systemic steroids intake, n (%) | 6 (6.3) | 6 (5.2) | 12 (5.7) |
DMARDs intake, n (%) | 26 (27.4) | 35 (30.4) | 61 (29.0) |
TNFα blocker intake, n (%) | 1 (1.1) | 4 (3.5) | 5 (2.4) |
Current smoking, n (%) | 24 (25.3) | 39 (33.9) | 63 (30.0) |